Net Realized Gain
The Company had investment sales and prepayments totaling approximately $48.1 and $12.2 million, respectively, for the fiscal years ended December 31, 2020 and 2019. Net realized gains over the same period totaled $0.2 million and $0.1 million, respectively. Net realized gains for fiscal year 2020 were primarily related to the sale of select assets. Net realized gains for fiscal year 2019 were primarily related to the exit of our investments in Centria Healthcare LLC and Tetraphase Pharmaceuticals, Inc.
Net Change in Unrealized Gain
For the fiscal years ended December 31, 2020 and 2019, net change in unrealized gain on the Company’s assets totaled $0.4 million and $0.7 million, respectively. Net unrealized gain for the fiscal year ended December 31, 2020 is primarily due to appreciation on our investments in RxSense Holdings LLC, Galway Partners Holdings, LLC and ENS Holdings III Corp. & ES Opco USA LLC, among others, partially offset by the reversal of previous recorded unrealized appreciation on our investments in Kingsbridge Holdings, LLC, MRI Software LLC and Enhanced Capital Group, LLC among others. Net unrealized gain for the fiscal year ended December 31, 2019 is primarily due to appreciation on our investments in Kingsbridge Holdings, LLC, KORE Wireless Group, Inc. and Edgewood Partners Holdings, LLC, among others, partially offset by unrealized depreciation on our investment in US Radiology Specialists, Inc., among others.
Net Increase in Unitholders’ Capital Resulting From Operations
For the fiscal years ended December 31, 2020 and 2019, the Company had a net increase in unitholders’ capital resulting from operations of $6.1 million and $0.5 million, respectively. For the same period, income per average unit was $0.70 and $0.15, respectively.
Financial Condition, Liquidity and Capital Resources
Our primary uses of cash are for (i) investments in portfolio companies and other investments to comply with certain portfolio diversification requirements, (ii) the cost of operations (including paying the Adviser), (iii) debt service of any borrowings, and (iv) cash distributions to our Unitholders.
Equity
During the period March 12, 2019 (commencement of operations) to December 31, 2020, on a net basis, the Company sold and issued 9,586,174 common units at an average price of $9.93 per unit, for net proceeds of $96.5 million. All of our outstanding units were issued and sold in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. Unfunded equity capital commitments totaled $229.5 million at December 31, 2020.
Debt
Revolving credit facility due February 2023 (the “SPV Facility”)—On February 27, 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into a $100 million SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up to $400 million. The stated interest rate on the Credit Facility is LIBOR plus 2.75% with no LIBOR floor requirement and the current final maturity date is February 27, 2023. The Credit Facility is secured by all of the assets held by SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75 million. There were $53.1 million of borrowings outstanding as of December 31, 2020 under the SPV Facility.
88